FDA Proposes Priorities For Cosmetic Ingredient Review: Mica, Probiotics, CBD
Nakissa Sadrieh, director of cosmetics at FDA and the agency’s CIR liaison, floated the three potential review priorities at the CIR Expert Panel’s April 8-9 meeting in Washington. It’s the most for-cause targets proposed by the agency in recent memory, and CIR leadership noted that they pose considerable challenges.
You may also be interested in...
Cosmetics Market In 2019: CBD, Microplastic And US Sunscreen Uncertainty Among Year’s Biggest Issues
The opportunity represented by cannabidiol, and the uncertain future for commonly used sunscreen active ingredients in the US and microplastic in the EU, were issues of high interest among cosmetics industry stakeholders in 2019.